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Patients with end-stage renal disease (ESRD) on maintenance
dialysis are predisposed to hepatitis B virus (HBV) and
hepatitis C virus (HCV) infection more than the general
population because of haemodialysis, blood transfusions,
exposure to invasive procedures, and nosocomial and
iatrogenic transmissions.1-3 Other risk factors may include
duration of ESRD,3, 4 duration of dialysis5 and mode of dialysis.4
Haemodialysis units have experienced outbreaks of HBV
infection, with fatal cases among patients and staff.  The HBV
prevalence rate varies from one dialysis unit  to another.  In
Europe the prevalence rate is reported to be 23 - 43%;16 other
reported rates are USA16 - 18%,6 Tunisia 18%, 7 France 2.2%,8
Russia 39 - 50%9 and South Africa 17%.6 Generally, more than
half of the infected patients on dialysis become persistent,
symptomless hepatitis B surface antigen (HBsAg) carriers
without biochemical evidence of hepatitis. 6 In addition, the
appearance of serological markers for HBV may be delayed by
as long as 6 - 12 months.  Because of the interpatient variation
in response to HBV infection, liver involvement in patients on
maintenance dialysis should be monitored using transaminase
activity over the period of dialysis.4-6 Some dialysis centres
have reported outbreaks of fulminant HBV infection indicating
that immunocompromised hosts, such as ESRD patients on
dialysis, may develop severe disease from HBV infection. 10
Studies carried out in various centres worldwide among
dialysis patients have shown  a prevalence of HCV of the order
of 8 - 36% in North America, 6,11 25 - 39% in South America, 3
1 - 36% in Europe, 12 17-51% in Asia,11 1.2 - 10% in New Zealand
and Australia,4-8 and 7 - 85% in South Africa. 13 False-negative
tests for anti-HCV have been reported in up to 33% of ESRD
patients on dialysis due to immunosuppression, 14 and per-
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Background. Patients with end-stage renal disease (ESRD) on
maintenance dialysis are predisposed to hepatitis B virus
(HBV) infection for a number of reasons.  In a similar way, the
prevalence of anti-hepatitis C virus (HCV) antibodies among
patients on chronic haemodialysis and peritoneal dialysis is
consistently higher than in healthy populations.  There are few
published data on these diseases in patients undergoing
maintenance dialysis in sub-Saharan Africa.
Objective. To determine the seroprevalence of HBV and HCV
in patients on maintenance dialysis.
Setting. Renal Unit, Kenyatta National Hospital, the largest
public referral and teaching hospital in Kenya.
Design. Cross-sectional descriptive study.
Study population. All 100 patients on maintenance dialysis
during the 9-month study period were evaluated.
Method. The following information was obtained from all the
patients: socio-demographic data, date of diagnosis of ESRD
and commencement of dialysis, and number of blood
transfusions.  Additionally, a history suggestive of hepatitis in
spouses was looked for and physical examination for tattoos
and other scars was carried out.  Laboratory investigations
included urea, electrolytes and serum creatinine, liver
enzymes, hepatitis B surface antigen (HBsAg),
immunoglobulin M anti-hepatitis B core antibody (IgM anti-
HBc), hepatitis B e antigen (HBeAg) and anti-HCV antibodies.
Student's t-test was used to assess the significance of the data
collected.
Results. The results were expressed as mean (±SD). Fifty-seven
males and 43 females were studied.  Mean age was 44.3 ± 14.6
years.  Ten patients (10%) had elevated aspartate
aminotransferase (AST) and alanine aminotransferase (ALT) 
(> 40 U/l for both).  
HBsAg was found in 8 patients (8%), IgM anti-HBc in 2%,
and HBeAg in none.  Anti-HCV antibody was found in 5%.
Six of the HBsAg-positive patients were on haemodialysis, the
other 2 on continuous ambulatory peritoneal dialysis (CAPD).
There was no coexistence of HBV and HCV markers.  Longer
duration of dialysis and the number of blood transfusions
were associated with an increased seroprevalence of HBV and
HCV.
Conclusion. There is a low seroprevalence of HBV and HCV
in our dialysis population.  This should not lead to
complaisance in screening for these potentially lethal
complications.
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sistent viraemia after resolution of clinical hepatitis occurs in 80
- 90% of dialysis patients.  The HCV-infected haemodialysis
patients develop high alanine aminotransferase (ALT) levels in
the months after exposure.  This suggests progressive liver
damage in this group of patients. 11 Therefore a high ALT level
has been used as a surrogate marker of HCV infection in
dialysis patients.15 HCV infection is usually confirmed by
demonstration of viral RNA. This is expensive, especially for
centres such as Kenyatta National Hospital Dialysis Unit,
which is not well established. 
The seroprevalence of HBV in the general population in
Kenya is reported to be 7 - 30% in studies using HBsAg as a
marker, while the seroprevalence of HCV, using anti-HCV
antibodies, is 0.2 - 0.9%. 16, 17 This makes the country highly
endemic for HBV, with a probable low endemicity of HCV.
Given that HBV and HCV seroprevalence is high in some well-
developed dialysis centres, sometimes with grave consequences,
and that there are scanty data on these issues in sub-Saharan
Africa (Kenya included), we decided to carry out a study on
the prevalence of some of the serological markers of the two
viruses in our dialysis unit, which is one of the largest in the
region.
Materials and methods
A total of 100 patients (57 males, 43 females) with ESRD on
maintenance dialysis (haemodialysis and continuous
ambulatory peritoneal dialysis (CAPD)) over a period of 9
months (March 1998 - November 1998) at the Kenyatta
National Hospital's Renal Unit were recruited into the study.
This comprised all patients on maintenance dialysis at that
time.  None of the patients had been vaccinated against HBV.
Five patients were HBsAg-positive and were undergoing
haemodialysis on an isolated machine and were excluded from
the study.
The study was approved by both the Department of Internal
Medicine, University of Nairobi, and the Kenyatta National
Hospital Ethical and Research Committee. Signed consent was
obtained from every patient.
The following information was obtained from patients and
their follow-up records:  socio-demographic data, date of
diagnosis of ESRD, date of starting dialysis and mode of
dialysis offered, duration of dialysis treatment and number of
blood transfusions.  Past surgical history was enquired about
and patients were asked if their sexual partners had ever had
evidence of presumed or confirmed hepatitis.  The patients
were also examined for tattoos and scarification.
Eight millilitres of blood were drawn from each patient and
divided into two aliquots of 4 ml each.  Serum was separated
from one aliquot soon after collection and immediately stored
at -15°C in a refrigerator for HBV and HCV serology.  The
other 4 ml of blood was used for analysis of creatinine, urea,
electrolytes and liver enzymes (aspartate aminotransferase
(AST) and alanine aminotransferase (ALT)).  These were done
using the Technicon RA1000 machine (Technicon RAsystems
No. SM-0034 D91 and No. SM 4-0137D91, 1996).  HBsAg was
analysed using reverse passive haemagglutination assay
(RPHA).  Immunoglobulin M (IgM) anti-HBc was assayed
using the enzyme-linked immunosorbent assay (ELISA)
method. HBeAg was analysed using the enzyme immunoassay
(EIA).  Anti-HCV was analysed using the AxSYM HCV version
3.0 microparticle enzyme immunoassay (MEIA) (Abbott
Diagnostic Laboratories, Germany).  The presence of liver
dysfunction was defined as elevated AST or ALT.
The raw data were entered into a computer and analysed
using the SPSS package.  The prevalence of HBV markers and
anti-HCV was obtained. The results were expressed  as means
(± standard deviation (SD)). Student's t-test was used to asses
the significance of the raw data obtained, a p-value of less than
0.05 being taken as statistically significant. The relationship
between the prevalence of the HBV markers, anti-HCV and
risk factors for the transmission of HBV and HCV was
determined.
Results
A total of 100 patients with ESRD on maintenance dialysis (82
haemodialysis, 18 CAPD) were recruited into the study. The
results are expressed as mean (±SD). The mean age of patients
was 44.0 ± 13.7 years for males and 42.74 ± 16.10 for females 
(p > 0.05) 
There was no statistically significant difference between the
mean age, duration of dialysis and number of blood
transfusions for males and females (p > 0.05) (Table I).
However, the patients on haemodialysis had been on dialysis
for significantly longer periods and had been exposed to more
blood transfusions than those on CAPD (p = 0.02, p = 0.027)
respectively.
Three patients (2 males and 1 female) had received blood
transfusions before developing chronic renal failure.  No
patient had tattoos or scarifications.
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Table I.  Demographic data, duration of dialysis and number of
blood transfusions 
Age (years ± SD) 42.35 ± 13.00 43.90 ± 16.75 0.0822
Male/female 43:37 12:6 0.0843
Duration of dialysis (yrs) 1.45 ± 1.41 1.40 ± 0.95 0.02
Blood transfusions 
during dialysis 5.48 ± 4.73 1.56 ± 0.87 0.027
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Prevalence of HBV markers (HBsAg, IgM anti-HBc,
HBeAg)
HBsAg was detected in 8 patients (8%) (4 males and 4 females).
Two of these patients also tested positive for  IgM anti-hepatitis
B core antibody (anti-HBc), making HBsAg the only useful
seroprevalence marker in this study because immunoglobulin
G (IgG) anti-HBc could not be done.  Six of the 8 patients were
on haemodialysis and 2 on CAPD.  The prevalence of the HBV
markers did not vary with the mode of dialysis (p = 0.44). Only
2 patients on CAPD  tested positive for HBsAg. This sample is,
therefore, inadequate for any significant differences to be
expected. The 8 patients with HBV markers did not have other
pre-dialysis risk factors to exposure to HBV infection such as
tattoos, history of surgery, the sexual partner having presumed
or confirmed evidence of hepatitis or previous blood trans-
fusions.  All the patients studied tested negative for HBeAg.
The mean age of patients on haemodialysis who tested positive
for HBsAg was  42.90 ± 13.97 years. They had received 7.25 ±
6.10 units of blood compared with  2.31 ± 0.97 units received by
the patients who tested negative for HBsAg (p < 0.001). They
had also been on haemodialysis for 1.74 ± 0.9 years compared
with 1.49 ± 1.10 years for patients who tested negative for
HBsAg (p = 0.015).
Prevalence of anti-HCV 
Anti-HCV was detected in 5 of the patients (5%) (4 males and 1
female, p = 0.36).  Patients who were anti-HCV-positive had
been on haemodialysis for 2.64 ± 1.20 years compared with 1.27
± 0.93 years for patients who tested negative for anti-HCV
(p = 0.018).  They had received 2.60 ± 1.80 units of blood
compared with 1.37 ± 0.93 units of blood for patients who
tested negative for anti-HCV ( p = 0.0183).  No patient on CAPD
tested positive for anti-HCV.
Relationship between number of blood transfusions
and HBsAg and anti-HCV status
Table II shows the relationship between the number of units of
blood transfused and the HBsAg and anti-HCV positivity.
The patients who tested positive for the viral markers had
had more blood transfusions (5.44 ±  4.72 units) than patients
who tested negative for the viral markers  (2.10 ± 1.07 units)
(p < 0.001).  The majority of the patients who were sero-positive
for HBV and HCV belonged to the group that had received 1 -
10 units of blood, but this was the largest group.
Relationship between duration of dialysis and
HBsAg, IgM antiHBc, HBeAg and anti-HCV
Table III shows the relationship between the duration of
dialysis and the prevalence of HBV and HCV markers.
The duration of dialysis for the patients who tested positive
for the viral markers was longer than for those who tested
negative for viral markers.  Patients who tested positive for
HBV markers (8 patients, 6 haemodialysis and 2 CAPD) had
been on dialysis for 1.90 ± 0.97 years, while those who tested
positive for anti-HCV (5 patients, all on haemodialysis) had
been on dialysis for 2.64 ± 1.23 years.  This duration was longer
than that for patients who tested negative for viral markers,
viz. 1.48 ± 1.32 years (87 patients, p = 0.02).  This shows a
significant statistical relationship between the duration of
dialysis and the presence of viral markers.  
Of the 8 patients on maintenance dialysis with evidence of
exposure to HBV, none tested positive for anti-HCV, and the
relationship between anti-HCV and HBV markers was not
statistically significant (p > 0.05) (Table IV).
Prevalence of deranged liver enzymes in
maintenance dialysis patients 
Three of the 10 patients with deranged liver enzymes on
maintenance dialysis were positive for viral markers (2 HBsAg
and IgM anti-HBc and 1 anti-HCV-positive) and had elevated
AST and ALT (p = 0.04) (Table V).  Deranged liver enzymes
Table II.  Number of blood transfusions and HBsAg and anti-
HCV status (%)
A n t i - H C V-
No. of transfusions No. of patients H B s A g - p o s i t i v e p o s i t i v e
0 2 0 0
1 - 10 7 5 7 (9.33) 4 (5.33)
11 - 20 2 3 1 (4.35) 1 (4.35)
Table III.  Duration of dialysis and seroprevalence of HBV and
HCV (%)
Duration of No. of HBsAg- IgM anti-HBc- HBeAg-
dialysis (yrs) patients positive positive positive Anti-HCV
< 1 53 2 (3.8) 1 (1.9) 0 0
1 -5 44 6 (13.6) 1 (2.3) 0 4 (9.9)
5.1 - 10 3 0 0 0 1 (33.3)
Table IV. Relationship of anti-HCV to HBV markers (HBsAg, IgM
anti-HBc and HBeAg)
Markers No. of patients Anti-HCV-positive
HBsAg-positive 8 0
HBsAg-negative 92 5
IgM antiHBc-positive 2 0
IgM HBc-negative 98 5
HBeAg-positive 0 0
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was defined as elevated AST and ALT.  Ten patients (10%) had
evidence of elevated liver enzymes.  Of these, 8 were on
haemodialysis and 2 on CAPD.  The 8 patients on
haemodialysis had elevated AST and ALT of between 50 - 75
U/l.  Two of the 8 patients tested positive for HBsAg and IgM
anti-HBc.  None tested positive for HBeAg.  Five patients
tested positive for anti-HCV and only 1 of them had elevated
AST and ALT.  The other 4 had normal liver enzymes.
Discussion
Despite the fact that maintenance dialysis has greatly improved
the prognosis and quality of life of patients with ESRD, their
impaired immune responses puts them at higher risk of
infection, including HBV infection.  Predisposition to the
development of other liver diseases with consequent elevation of
transaminases also occurs in these patients.4 , 6 , 1 4
In our study population, the prevalence of HBsAg was 8%
(50% males). Our patients who were positive for HBsAg had
tested negative pre-dialysis. The HBV infection correlated with
the duration of dialysis and blood transfusions and may,
therefore, have been acquired through haemodialysis or blood
transfusion. Although blood for transfusion is screened for
HBV, blood transfusion still remains a major risk factor for
transmission of HBV infection.  HBV DNAhas been detected in
serum and peripheral blood mononuclear cells of HBsAg-
negative haemodialysis patients and staff, and they are
therefore potentially infectious to other patients and staff. 18
Absence of HBsAg does not therefore exclude the presence of
HBV infection. Regular periodic screening for HBV markers in
patients on dialysis is therefore important.  We note in this
study that subsequent screening revealed that previously viral
hepatitis seronegative patients had now seroconverted.  There
could also be de novo HBV infection secondary to the
immunodeficient state in these patients, as has been reported.6
The prevalence of HBsAg in this patient population is much
the same as that reported in the general Kenyan population,
viz.  7 - 30%.16 It should, however, be noted that the dialysis
population is highly selected and usually screened pre-dialysis.
The study population here was HBsAg-negative on entrance to
the dialysis programme. Additionally, this prevalence is also
lower than that reported in other parts of the world such as
Europe, the USA, Russia, Tunisia and South Africa.6,7,9,10 This
may be related to the fact that patients in these better
developed centres stay on dialysis for longer periods than in
our centre.                                 
The prevalence of  anti-HCV was 5% (80% male).  Males
have been reported to have a higher prevalence of HCV
infection than females19 and DuBois and colleagues20 observed
that male haemodialysis patients infected with HCV had a
significantly higher concentration of serum HCV RNAthan
females. However, there are currently no other data available
regarding gender-related differences in the natural history of
HCV infection and our data are too small to allow for any
reasonable conclusions.  The prevalence of 5% is much higher
than the 0.2 - 0.9% reported in our blood donors and is higher
than the 0% reported in the dialysis population in 1995.17
Despite the fact that the prevalence is much lower than that
reported by other countries such as North America (8 - 36%),4
South America (25 - 39%),3 Europe (1 - 36%),12 Asia (17 -  51%), 4
New Zealand and Australia (1.2 - 10%)4 and South Africa (7 -
85%),13 it shows a definite increase and should therefore not be
treated lightly.  Moreover, it is a well-recognised fact that the
prevalence of HCV varies widely from country to country and
from one dialysis centre to the next even within the same
country.4 All our 18 patients on CAPD tested negative for anti-
HCV, the 5% positivity being restricted to the haemodialysis
patients.  Although our numbers are small, patients on CAPD
have been reported to be at lower risk for HCV infection4 and
in contrast to haemodialysed patients, duration of dialysis does
not appear to be a risk factor for acquiring HCV infection.21
It may be noted that blood donors were school and college
students and army personnel; few individuals and relatives of
patients voluntarily donated blood. The blood was screened
using the ELISAmethod, with a sensitivity and specificity of
97% and 99% respectively. Viruses in the blood could have
been in the window period or there could have been
contamination from the other HBsAg-positive patients who
were otherwise isolated within the dialysis unit but excluded
from the study.
Our patients on haemodialysis for a short duration and those
who had received few blood transfusions, tested negative for
the viral markers.  This suggests that the duration of
haemodialysis and the number of blood transfusions are
significant risk factors for HBV and HCV transmission, as been
reported by others. 22 Thus, the risk of acquiring HCV infection
on haemodialysis has been estimated at 10% per year.  In our
study, there was no relationship between HCV antibodies and
HBV antigenaemia in patients undergoing maintenance
haemodialysis as has recently been alluded to.  The human
immunodeficiency virus (HIV) causes significant impairment
of the immune system and a higher rate of HBV replication.23
Two of our patients on CAPD were HIV-infected and were
positive for HBsAg. However, they had also received blood
transfusions so we cannot be categorical about the role of their
HIV status.
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Table V. Correlation between elevated AST and ALT and the
presence or absence of the viral markers 
H B s A g / I g M
a n t i - H B c - A n t i - H C V- H B s A g / a n t i -
Patients (N) p o s i t i v e p o s i t i v e H C V- n e g a t i v e p- v a l u e
A S T / A LT > 40 IU/l 1 0 2 1 7 0 . 0 4
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We found evidence of liver dysfunction manifested by
elevated ALT and AST in 10% of our patients (8 on
haemodialysis and 2 on CAPD).  This compares with the figure
of 10 - 44% reported by Pereira et al.4 Two of the 8 patients on
haemodialysis had elevated AST and ALT and also tested
positive for HBsAg and IgM antiHBc, and 1 of the 8 patients
tested positive for anti-HCV.  This reached statistical
significance, suggesting an association with elevated liver
enzymes in the majority of viral marker-positive patients.  The
general prognosis of hepatitis in patients on maintenance
dialysis appears to be  benign.  Most of these patients have no
clinical symptoms but do have episodic mild increases in
serum ALT and AST.4,6,24 They therefore become carriers who
are potentially infectious to other patients and staff.  Their HBV
and HCV infection is only discovered by routine serological or
biochemical testing during blood donation or routine health
screening.24 They should therefore be monitored over the
period of dialysis using liver transaminases as surrogate
markers of HBV and HCV infection.4,6
We would like to express our gratitude to Drs B A R Ogutu and
L Nganga  for providing technical assistance at the Kenya Medical
Research Institute Laboratories and to the Deputy Director, Clinical
Services, Kenyatta National Hospital, for allowing us to publish the
data.
References
1. Saraswat S, Banerjee K, Chaudhry N, et al. Post transfusion hepatitis B following 
multiple transfusions of HBsAg negative blood. J Hepatol 1996; 25: 639-643.
2. Cendorolo NM, Draibe SA, Silva EA, et al.  Incidence of and risk factors for HBV and HCV
infection among HD and CAPD patients: evidence for environmental transmission.  Nephrol
Dial Transplant 1995; 10: 240 - 246.
3. Muller GY, Zabaleta ME, Arminio A. Risk factors for dialysis-associated hepatitis C in
Venezuela.  Kidney Int 1992;  41: 1055 - 1058.
4. Pereira BJG, Levey AS.  Hepatitis C virus infection in dialysis and renal transplantation.
Kidney Int 1997;  51: 981 - 999.
5. Hardy NM, Sandroni S, Danielson S, Wilson WJ.  Antibody to hepatitis C virus increases
with time on dialysis.  Clin Nephrol 1992;  38: 44 - 48.
6. Koeler PM. Dialysis associated hepatitis. In: Horl WH, Ronco C, Winchester JF, Koch KM,
Lindsay RM, eds. Replacement of Renal Function by Dialysis . 5th ed. Dordrecht: Kluwer
Academic Publishers, 2003: 905-918.
7. Savin EA, Vasil'ev AN, Paskonkina OV, Os'Mirko TV. The characteristics of the epidemic
process in hepatitis B, C and D in haemodialysis units and the experience of the vaccinal
prevention of HBV infection in a delimited population.  Russia.  Ter Arkh 1995; 67: 13 - 15.
8. Goudeau A, Dubois F.  Incidence and prevalence of hepatitis B in France.  Vaccine 1995; 13:
suppl 1, S22 - S25.
9. Shaskhgil'dian IV, Khukhlovich PA, Savin EA, et al. Risk of infection with hepatitis B and C
viruses of medical workers, patients in haemodialysis wards, and vaccine prophylaxis of
hepatitis B infection in this population.  Russian.  Vopr Virusol 1994;  39: 226 - 229.
10. Feitelson MA, Duan LX, Guoj K, et al. Precore and X region mutants in hepatitis B virus
infections among renal dialysis patients.  J Virol Hep 1995;  2: 19 - 31.
11. Cheng CH, Cheng TC, Lee SH, Shu KH, Wu MY.  Increased serum transaminase levels in
hepatitis C infectious haemodialysis patients:  correlation with HCV viraemia and
immunoblot.  Nephrology 1997; 3: suppl 1,  164.
12. Barril G, Traver JA. Hepatitis virus prevalence in relation to modality of dialysis. 
Results after 4 years in 97 Spanish centers.  Nephrology 1997;  3:  suppl 1,  168.
13 Soni PN, Tait DR, Kenoyer DG.  Hepatitis C virus antibodies among risk groups in a 
South African area endemic for hepatitis B virus. J Med Virol 1993;  40: 65 - 68.
14 Fang J, Lav J.  Controlling hepatitis C, a killer unmasked.  J Innov Health 1997;  2: 38 - 41.
15. Ng YY, LeeSD, Wu SC, Huang GTP.  Hepatitis C viral infection in haemodialysis  
patients:  Clinical and molecular studies.  Nephrology 1997; 3: suppl 1,  166.
16. Okoth FA. Viral hepatitis. East Afr Med J 1996; 73: 308-312.
17. Ilako FM, Mcligeyo SO, Riyat  MS, Lule GN, Okoth FA, Kaptich  D. The prevalence
of hepatitis C virus antibody in renal patients, blood donors and patients with chronic liver
disease in Kenya. East Afr Med  J 1995; 72: 362-364.
18. Oesterreicher C, Hammer J, Koch U, Pfeffel F, Sunder-Plassmann D, Muller C. HBV and
HCV genome in peripheral blood mononuclear cells in patients undergoing chronic
haemodialysis.  Kidney Int 1995;  48: 1967 - 1971.
19. Alter MJ, Margolis HS, Krawezynski K, et al.  The natural history of community-acquired
hepatitis C in the United States.  The Sentinel Countries Chronic non-A, non-B Hepatitis
Study Team.  N Engl J Med 1992;  327: 1899 - 1905.
20. DuBois DB, Gretch D, Dela Rosa C, et al. Quantitation of hepatitis C viral RNAin sera of
haemodialysis patients.  Gender related differences in viral load.  Am J  Kidney Dis 1994;  24:
795 - 801.
21.  Niu MT, Alter MJ, Kristensen C, Margolis HS.  Outbreak of haemodialysis-associated non-A,
non-B hepatitis and correlation with antibody for hepatitis C virus.  Am  J Kidney Dis 1992;
19: 345 - 352.
22. Dussol B, Chicheportiche C, Cantaloube JF, et al. Detection of hepatitis C infection by
polymerase chain reaction among haemodialysis patients.  Am  J Kidney Dis 1993; 22: 574 -
580.
23. Saho JF, Haukenes G, Yangi E, Vollset SE. Association of HBV and HIV infections in
Tanzanian population groups.  Eur J Clin Microbiol Infect Dis 1993;  12: 62 - 64.
24. William M, Lee MD.  Hepatitis B virus infection.  N Engl  J Med 1997;  337: 1733 - 1745.
Accepted 29 October 2002.
